The global Acute Bacterial Skin and Skin Structure Infections Market deals with products that are used for the treatment of acute bacterial skin and skin structure infections. These products include antibiotics like cephalosporins, carbapenems, glycopeptides, lipoglycopeptides, aminoglycoside, oxazolidinones, tetracyclines and others. The rising incidence of bacterial skin diseases like impetigo, cellulitis, cutaneous abscesses etc. has increased the demand for effective treatment options. The global Acute Bacterial Skin and Skin Structure Infections Market is estimated to be valued at US$ 3,466.6 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing incidence rate of bacterial skin infections is one of the major trends driving the growth of the Acute Bacterial Skin and Skin Structure Infections Market. According to the Centers for Disease Control and Prevention (CDC), approximately 14 million people visit a doctor annually for impetigo in the U.S. alone. Cellulitis affects 4 to 5 people per 1,000 population per year. The rising prevalence of such bacterial skin infections increases the demand for effective antibiotics and other treatment options for acute bacterial skin and skin structure infections. This is positively impacting the revenues in the market over the forecast period.
Segment Analysis
The global acute bacterial skin and skin structure infections market is segmented based on disease type, treatment type, route of administration, distribution channel, and end user. The disease type segment is further bifurcated into impetigo, cellulitis, boils, and others. The cellulitis segment currently dominates the market due to high occurrence of cellulitis cases globally every year.
Key Takeaways
The global Acute Bacterial Skin and Skin Structure Infections market is expected to witness high growth.
Regional analysis: The acute bacterial skin and skin structure infections market in North America is expected to hold the largest market share over the forecast period. This is attributed to the rising prevalence of skin infections coupled with growing incidence of chronic diseases requiring treatment in the region.
Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.
No comments:
Post a Comment